Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037396 · ClinicalTrials.gov registry record
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 9,457
- Enrollment target
NCT05037396: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05037396 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9,457 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05037396 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 9,457 participants
- Enrollment target
Study Summary
This was a retrospective cohort study to assess the treatment history, demographic characteristics, clinical characteristics, and early treatment patterns of patients who received brolucizumab for neovascular age-related macular degeneration using IRIS Registry.
Primary Outcome
To describe anti-VEGF treatment status (naive or switcher) in patients with wet AMD who initiated brolucizumab
Interventions
- DRUG Brolucizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,457 participants |
| Start Date | 2020-03-05 |
| Est. Completion | 2020-08-01 |
What the finished NCT05037396 record still lists
NCT05037396 is an observational study that tracks outcomes without assigning an intervention. Its 9,457 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Brolucizumab is the first listed.
NCT05037396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05037396 about?
NCT05037396 is a clinical study titled "Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab". This was a retrospective cohort study to assess the treatment history, demographic characteristics, clinical characteristics, and early treatment patterns of patients who received brolucizumab for neovascular age-related macular degeneration using IRIS Registry.
What is the current status of trial NCT05037396?
This trial is currently completed. The enrollment target is 9,457 participants. The study started on 2020-03-05. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT05037396?
The interventions under investigation include: Brolucizumab (DRUG).
Who is sponsoring clinical trial NCT05037396?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI